Concepedia

Kevin A. Hay

KA

Statistics

Publications

31

Citations

6.8K

H-Index

25

Active since

2010

Affiliations

University of British Columbia(Current)

Fred Hutch Cancer Center

University of Washington

University of Liège

Méditerranée Infection Foundation

Kevin A. Hay is an author at University of British Columbia specializing in medicine, immunotherapy, and chimeric antigen receptor t-cell therapy.

ORCID

Publications per year

2010–2024

31

Publications

31

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Juliane Gust, Kevin A. Hay, Laïla‐Aïcha Hanafi et al. · Cancer Discovery · 2017 · 1.4K citations · Full text

, , +17

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Kevin A. Hay, Laïla‐Aïcha Hanafi, Daniel Li et al. · Blood · 2017 · 1.1K citations · Full text

, , +16

Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

Gilbert Habib, Paola Anna Erba, Bernard Iung et al. · European Heart Journal · 2019 · 867 citations · Full text

, , +15

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

Cameron J. Turtle, Kevin A. Hay, Laïla‐Aïcha Hanafi et al. · Journal of Clinical Oncology · 2017 · 657 citations

, , +17

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

Joshua A. Hill, Daniel Li, Kevin A. Hay et al. · Blood · 2017 · 566 citations · Full text

, , +15

1–5 of 31